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This thesis con[ains a number of studies in which clinical data obtained from a series
of lung cancer patiens at diagnosis, during Eeatment. and Íre development of drug re-
sistance have been collected. A series of new parameters obtained from biopsy speci-
mens, marïow aspirates, and biopsy specimen derived cell lines, was collected in these
patients. It was attempted to correlate tïese laboratory findings wiÍr the clinical infor-
mation.
In chapter I a metiod is described enabling Íte routine assessment of phenotypic
differences using immunohistochemistry, in small lung cancer biopsy specimens. This
can be done without interfering with the normal histopathological evaluation of Íre
case. This is important because the WHO classifications of lung cancer emains the re-
ference point to which monoclonal antibody based subclassifications should be com-
pared.
To distinguish bronchial carcinoid tumors and small cell lung cancer may be very
difltcult using clinical, cytopathological and/or biochemical parameters alone. Chapter
II describes two patients who were initially judged to suffer from small cell lung can-
cer. Clinical data cast doubt upon this diagnosis, and in one patient a very long natural
history, exeeding 32 years, could be reconstructed. Small cell lung cancer, atypical car-
cinoid and carcinoid all share a series of neuroendocrine differentiation features but
may behave completely different.
In Chapter III the results are described of giving a reinduction chemotherapy with
the induction regimen. In most SCLC patients a remission of the tumor can be induced
by short term (5 cycles) polychemotherapeutic reaÍnent with cyclophosphamide, to-
poside and doxorubicin. The duration of the remission seldomly exeeds 2 years. These
results can not be improved by increasing the number of treatment cycles given. It is
generally assumed that the effect of a reinduction polychemotherapeutic rrearÍnent in
relapsing small cell lung cancer is minimal because no non-cross resistant drug sche-
dules are available. We have treated relapsing small cell lung cancer, with the same
combination of drugs which was used in the induction Írerapy. This resulted in a se-
cond response in 23 out of37 patients. Factors influencing the occunence ofa second
relapse were: A complete response after fte first five cycles , and a first response dura-
tion > 34 weeks.
A detailed series of in virro studies have been described in Chapter IV. Three small
cell lung cancer (SCLC) cell lines have been established from one patient during lon-
gitudinal follow-up. During this period the tumor changed from sensitive !o complete-
ly resistant o (chemo)therapy. A phenotypical and functional characÍeization of the
different cell lines is given in combination with the matching clinical data. In vitro pa-
rameters which were proposed to reflect the development of drug resistance did not
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monoclonal antibodies was slightly decreased in both recurrent disease biopsy speci-
mens and cell lines.
In Chapter V it is shown tlat, for the detection of metastasis in bone marrow of pa-
tients with small cell lung cancer, immunofluorescence with a monoclonal antibody
detecting a SCLC related membrane antigen (MOC 1) may be used. This procedure
was performed on 53 bone marrow aspirates obtained from 30 patients. In 63Vo of the
patients MOC-l reactive cells were detected. Simultaneous histopathological examina-
tion of the bone marrow biopsies detected tumor cells in 20Va of the cases. Especially
for the selection of patients who might benefit from an adjuvant radio and/or surgical
therapy this procedure may be rewarding.
Chapter VI inventrrizes tlre expression of intermediate sized filament proteins cy-
tokeratin 10 and cytokeratin 18 using a monoclonal antibody guided immunohistologi-
cal method. This to detect subgroups within small cell lung cancer that might have cli-
nical relevance. Reactivity with the antibodies was subsequently correlatÊd tD clinical
data. An increased expression of cytokeratin 18 was observed in metastatic SCLC lesi-
ons. In Íris context it is of interest hat cytokeratin 18 is not expressed in the "variant"
type of small cell lung cancer, the proposed in vitro counterpart of therapy resistant
small cell lung cancer.
In Chapter VII the results of staining biopsy-specimens with a panel of monoclonal
antibodies, directed against antigens, related to a neuroendocrine and epithelial diffe-
rentiation state, are presented. This panel was prospectively applied to a series of small
cell lung cancer specimens obtained before the induction polychemotherapy. No diffe-
rences in panel reactivity were noÍed between partial and complete responders.
Neuroendocrine differentiation antigens were not expressed in two patients who failed
to respond to the induction polychemotherapeutic regimen. A thiÍd SCLC specimen
wittrout neuroendocrine differentiation antigens, was obtained from a small cell lung
cancer patient in whom a post surgical pathological staging revealed no metastasis.
This indicates that SCLC without neuroendocrine differentiation antisens contains a
group of tumors clinically mimicing non-SCLC.
Chapter VIII describes the neuroendocrine differentiation in a series SCLC tumor
biopsy specimens obtained either before induction chemotherapy, or, at relapse. It was
found that Íhe overall expression of neuroendocrine differentiation antigens was decre-
ased in the recurrent disease group. This decrease was especially clear for the antigens
recognized by the monoclonal antibodies MOC-21 and MOC-32. When the recunent
disease gtoup was further suMivided into cases either responding or non-responding
to subsequently given reinduction chemotherapy, it became appaÍent hat the observed
decrease in neuroendocrine antigen expression was largely confined to the non-
responder subgroup. The development of clinical resistance in SCLC may be accom-
panied by loss of specific neuroendocrine f atures. Immunohistological staining visu-
alizes such a change. This finding should be aken into account in deciding whether an




In most SCLC tumors properties compatible with a neuroendocrine differentiation can
be recognised both in vitro and in vivo using monoclonal antibodies. Similar proper-
ties can be recognised in a minority of non SCLC nrmors. To investigate whether clini=
cal behaviour of these non-SCLC tumors in which neuroendocrine properties could be
recognised mimiced SCLC, clinical data of l4l patients were analysed in Chapter IX.
Several parameters which were thought to indicate resemblances between this non-
SCLC subgroup and SCLC were assessed. However survival, stage distribution, and
the phenotype in metastatic lesions did not support a hypothesis suggesting resemblan-
ces in tumor biology between this non-SCLC subgroup and SCLC.
In conclusion this study shows that:
Phenotypic parameters obtained from three SCLC derived cell lines obrained du-
ring longitudinal follow-up in one patient only partially reflected the development of
drug resistance. We could not recognize the "variant" phenotype in the cell line obtai-
ned from a biopsy specimen at second recuïence of the SCLC tumor. Results of the
in vitro drug sensitivity assay were in agïeement with the treaÍnent status of the tumor.
Immunohistochemical staining can be performed in all diagnostic specimens with-
out interfering with normal histological work-up.
Using a monoclonal antibody guided assay, the detection rate of bone marrow me-
tastasis of SCLC increased three-fold. Using this technique it is possible to select those
patients amongst "complete responders" according to conventional staging procedures,
who have more minimal residual disease. This patient category may be candidate for
potentially loxic adjuvant therapies such as radiotherapy or surgery. It may also select
patients for adjuvant therapy with lymphokine activated killer cells. In animal experi-
ments it was shown that LAK cell therapy is useful especially if only small amounts of
tumor cells have io be killed.
A heterogeneity of neuroendocrine markers expression could be demonstrated in
lung cancer using a monoclonal antibody guided staining portocol. In SCLC a sub-
group is revealed charactarizeA by a decreased expression of neuroendocrine differen-
tiation antigens. This subgroup is less responsive to chemotherapy and might emerge
during chemotherapeutic treatment of neuroendocrine marker positive SCLC. In
non-SCLC, a series of clinical parameters obtained from patients with neuroendocrine
markers on their tumors, did not disclose a seperate clinical entity.
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